CA-LIVEACTION
10.8.2021 15:02:04 CEST | Business Wire | Press release
SITA, the leading IT provider to the air transport industry, and LiveAction , the leader in network performance management, today announced the availability of a new reporting solution that gives customers complete visibility and service assurance across WAN and SD-WAN deployments. Based on LiveAction’s LiveSP , the SITA SDN Reporting Platform is available as part of SITA Service Management Assurance, an industry-leading Service Management offering that helps customers achieve maximum value from SITA subscribed services.
LiveAction provides end-to-end visibility into network and application performance from a centralized, single pane of glass dashboard. The platform unifies networking data by collecting, analyzing and reporting on diverse network telemetry datasets, allowing organizations to optimize network, application and end-user performance. This helps network operations teams improve visibility across the entire hybrid network and track network usage, application performance, SD-WAN performance, COS information, cloud traffic usage, network latency and much more. Designed for service providers, LiveSP enables SITA to provide enhanced customer visibility and business insights for SITA Connect services – offering secure, reliable, and flexible network connectivity solutions that deliver ever-improving passenger experiences globally.
“Partnering with LiveAction has helped us develop a world-class service management offering for software-defined networking (SDN), including the co-development of unique reporting features that bring real value to our customers,” said Martin Smillie, Vice-President of Communications and Data Exchange at SITA. “The out-of-the-box integration with existing SDN vendors has reduced time to market with a robust and comprehensive solution.”
With many large airline customers already onboarded in the platform, SITA will be further enhancing the offering by integrating LiveAction LiveWire, a network packet capture solution. This will enable customers to extend network visibility and application troubleshooting and conduct deep forensic analysis if needed.
“Today’s networks are complex and changing rapidly. Having complete visibility into network and application performance is critical to delivering high-performance network services and being able to troubleshoot issues that arise,” said Stephen Stuut, Chief Executive Officer at LiveAction. “We’re excited to be working with SITA to help ensure their customers have world class connectivity and performance across global networks. This has been a complete team effort on both sides.”
For more information on SITA Service Management Assurance and the new reporting solution with LiveSP go to SITA | SITA Service Management .
About SITA
SITA is the air transport industry's IT provider, delivering solutions for airlines, airports, aircraft and governments. Our technology powers more seamless, safe and sustainable air travel. For further information, go to www.sita.aero .
About LiveAction
LiveAction provides end-to-end visibility into network and application performance from a single pane of glass. This gives enterprises confidence that the network is meeting business objectives, offers IT administrators full visibility for better decision making, and reduces the overall cost of operations. By unifying and simplifying the collection, correlation and presentation of network and application data, LiveAction empowers network professionals to proactively and quickly identify, troubleshoot and resolve issues across complex networks. Learn more at https://www.liveaction.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom